Cargando…

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma. Benralizumab is charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Yasuhiko, Aoki-Saito, Haruka, Kamide, Yosuke, Sato, Makiko, Tsurumaki, Hiroaki, Yatomi, Masakiyo, Ishizuka, Tamotsu, Hisada, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960447/
https://www.ncbi.nlm.nih.gov/pubmed/35359852
http://dx.doi.org/10.3389/fphar.2022.865318
_version_ 1784677385388425216
author Koga, Yasuhiko
Aoki-Saito, Haruka
Kamide, Yosuke
Sato, Makiko
Tsurumaki, Hiroaki
Yatomi, Masakiyo
Ishizuka, Tamotsu
Hisada, Takeshi
author_facet Koga, Yasuhiko
Aoki-Saito, Haruka
Kamide, Yosuke
Sato, Makiko
Tsurumaki, Hiroaki
Yatomi, Masakiyo
Ishizuka, Tamotsu
Hisada, Takeshi
author_sort Koga, Yasuhiko
collection PubMed
description Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma. Benralizumab is characterized by antibody-dependent cell-mediated cytotoxicity activity, giving them specific and rapid anti-IL-5α receptor binding abilities and the ability to target a high number of eosinophils in tissues as well as peripheral blood. Recently, reports on the efficacy of benralizumab as a treatment for EGPA have been published, along with reports on some cases that are difficult to treat with existing oral corticosteroids and mepolizumab. Therefore, we focus on the perspective of the efficacy and safety of benralizumab as a treatment for EGPA patients with steroid dependence in this review. A total of 41 patients with EGPA were treated with benralizumab. After the introduction of benralizumab, oral corticosteroids could be reduced to 10 mg/day or less in all cases and to less than 5 mg/day in 80% or more of the cases. Discontinuation of oral corticosteroids was achieved in more than 40% of patients with EGPA. Benralizumab was effective in patients with mepolizumab-refractory EGPA and intractable cardiac and neuropathy complications. Efficient elimination of eosinophils is expected to improve the remission rate of EGPA with benralizumab treatment. Although the total number of patients was small, benralizumab was safe and tolerable in a wide range of age groups, suggesting efficacy in severe cases with EGPA.
format Online
Article
Text
id pubmed-8960447
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89604472022-03-30 Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis Koga, Yasuhiko Aoki-Saito, Haruka Kamide, Yosuke Sato, Makiko Tsurumaki, Hiroaki Yatomi, Masakiyo Ishizuka, Tamotsu Hisada, Takeshi Front Pharmacol Pharmacology Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma. Benralizumab is characterized by antibody-dependent cell-mediated cytotoxicity activity, giving them specific and rapid anti-IL-5α receptor binding abilities and the ability to target a high number of eosinophils in tissues as well as peripheral blood. Recently, reports on the efficacy of benralizumab as a treatment for EGPA have been published, along with reports on some cases that are difficult to treat with existing oral corticosteroids and mepolizumab. Therefore, we focus on the perspective of the efficacy and safety of benralizumab as a treatment for EGPA patients with steroid dependence in this review. A total of 41 patients with EGPA were treated with benralizumab. After the introduction of benralizumab, oral corticosteroids could be reduced to 10 mg/day or less in all cases and to less than 5 mg/day in 80% or more of the cases. Discontinuation of oral corticosteroids was achieved in more than 40% of patients with EGPA. Benralizumab was effective in patients with mepolizumab-refractory EGPA and intractable cardiac and neuropathy complications. Efficient elimination of eosinophils is expected to improve the remission rate of EGPA with benralizumab treatment. Although the total number of patients was small, benralizumab was safe and tolerable in a wide range of age groups, suggesting efficacy in severe cases with EGPA. Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960447/ /pubmed/35359852 http://dx.doi.org/10.3389/fphar.2022.865318 Text en Copyright © 2022 Koga, Aoki-Saito, Kamide, Sato, Tsurumaki, Yatomi, Ishizuka and Hisada. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Koga, Yasuhiko
Aoki-Saito, Haruka
Kamide, Yosuke
Sato, Makiko
Tsurumaki, Hiroaki
Yatomi, Masakiyo
Ishizuka, Tamotsu
Hisada, Takeshi
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
title Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
title_full Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
title_fullStr Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
title_full_unstemmed Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
title_short Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
title_sort perspectives on the efficacy of benralizumab for treatment of eosinophilic granulomatosis with polyangiitis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960447/
https://www.ncbi.nlm.nih.gov/pubmed/35359852
http://dx.doi.org/10.3389/fphar.2022.865318
work_keys_str_mv AT kogayasuhiko perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT aokisaitoharuka perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT kamideyosuke perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT satomakiko perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT tsurumakihiroaki perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT yatomimasakiyo perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT ishizukatamotsu perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis
AT hisadatakeshi perspectivesontheefficacyofbenralizumabfortreatmentofeosinophilicgranulomatosiswithpolyangiitis